ALG 10000
Alternative Names: ALG-10000Latest Information Update: 30 May 2025
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Oligonucleotides
- Mechanism of Action Hepatitis B surface antigen expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 30 May 2025 Discontinued - Preclinical for Hepatitis B in USA (unspecified route) prior to May 2025 (Aligos Therapeutics pipeline, May 2025)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 21 Jun 2021 Pharmacodynamics data from in vitro studies in Hepatitis B presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2021 (ILC 2021)